Zhongguancun: Duoduo Pharmaceutical's tramadol hydrochloride injection passes consistency evaluation.

The announcement of Zhongguancun, its subsidiary Dodo Pharmaceutical's tramadol hydrochloride injection has passed the generic drug quality and efficacy consistency evaluation. The drug is an injection, with a specification of 2ml:100mg, produced by Dodo Pharmaceutical. In 2024, the sales of tramadol hydrochloride injection in domestic hospital terminal samples reached 230 million yuan, and in the first quarter of 2025, the sales amounted to 93 million yuan. As of the disclosure date of the announcement, 6 companies have passed the consistency evaluation for this drug, with a total research and development investment of 7.1533 million yuan. Passing the consistency evaluation is conducive to enhancing the competitiveness of the drug market and has a positive impact on the company's operating performance.